Nervonik, a clinical-stage medical device company focused on next-generation peripheral nerve stimulation, announced it has secured $52.5 million in an oversubscribed Series B financing round. The round was led by Amzak Health, with participation from Elevage Medical Technologies, U.S. Venture Partners, Lumira Ventures, Foothill Ventures, and Shangbay Capital.
The funding will support continued development and commercialization of Nervonik’s peripheral nerve stimulation system, including expansion of its proprietary sensing capabilities. The company is advancing a platform designed to integrate stimulation with real-time physiological feedback, enabling more precise and personalized therapy for patients suffering from chronic pain.
Nervonik’s technology incorporates the ability to record biomarkers such as evoked compound action potentials using implantable leads. Early results from its first-in-human study demonstrate the system’s potential to enhance therapy effectiveness by adapting to patient-specific physiological signals, positioning the company within the emerging field of bioelectronic medicine.
The financing comes as peripheral nerve stimulation gains traction as a treatment option, supported by growing clinical evidence and increasing adoption across chronic pain indications. Nervonik aims to use the new capital to accelerate its clinical programs and prepare for broader commercialization of its platform.
KEY QUOTES:
“Nervonik is building a fundamentally differentiated neuromodulation platform that integrates stimulation with advanced sensing to deliver more precise and personalized therapy. This financing enables us to accelerate our clinical programs, prepare for commercialization, and bring a truly intelligent, next-generation therapy to the patients who need it most.”
Aydin Babakhani, CEO and Founder, Nervonik
“Peripheral nerve stimulation is at an inflection point, with expanding clinical evidence and growing adoption in the treatment of chronic pain. Aydin and the Nervonik team have developed a highly differentiated technology platform that we believe has the potential to meaningfully improve the patient experience, and they are exceptionally well-positioned to capitalize on this opportunity. We are excited to lead this financing and to support the company through its next phase of growth.”
Anthony Natale, MD, Partner, Amzak Health
